Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2DX-guided treatment for early-stage HER2-positive breast cancer
2025-521040-37-00Phase 3Authorised
- Sponsor
- IDIBAPS
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of trastuzumab, pertuzumab, trastuzumab emtansine, paclitaxel, docetaxel and 4 more in breast cancer (2 arms), sponsored by IDIBAPS. Primary endpoints: Global health status quality of life superiority and Fatigue quality of life superiority. Planned start Nov 2025; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521040-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521040-37-00.